Barrick Gold Shares Gain 6%

Shares of Barrick Gold Corporation (GOLD) are gaining over 6% on Monday morning.

GOLD is currently trading at $16.90, up $0.99 or 6.19%, on the Nasdaq. The stock opened its trading at $16.60 after closing Friday’s trading at $15.91. The stock has traded between $13.01 and $25.99 in the past 52-week period.

Barrick Gold engages in the exploration, mine development, production, and sale of gold and copper properties. It has ownership interests in producing gold mines that are located in Argentina, Canada, Côte d’Ivoire, the Democratic Republic of Congo, the Dominican Republic, Mali, Tanzania, and the United States.

Seagen Jumps 15% As It Agrees To Be Acquired By Pfizer For $43 Bln

Shares of Seagen Inc. (SGEN) jumped over 15% on Monday morning after the company announced a deal to be acquired by drug giant Pfizer Inc. (PFE).

SGEN is currently trading at $198.65, up $26.04 or 15.09%, on the Nasdaq. The stock opened its trading at $173.64 after closing Friday’s trading at $172.61. The stock has traded between $105.43 and $199.78 in the past 52-week period.

Pfizer will acquire Seagen for $229 per share, implying an enterprise value of $43 billion. The companies expect to complete the merger in late 2023 or early 2024.

Seagen is a biotechnology company developing and commercializing monoclonal antibody-based therapies for the treatment of cancer. The company expects to generate approximately $2.2 billion of revenue in 2023, representing 12% year-over-year growth.

Skip the Flight and the Ferry With ‘Food of the Italian Islands’

Dive into Katie Parla’s new cookbook, add a little spice to your coffee and more.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Florence Fabricant

BILL Holdings Gains 10%

BILL Holdings, Inc. (BILL) shares are gaining more than 10 percent on Monday morning trade after reaching a year-to-date low on March 10. There were no corporate announcements from the company today.

Currently, shares are at $75.08, up 9.82 percent from the previous close of $68.35 on a volume of 3,658,079.

European Economic News Preview: Germany Factory Orders Data Due

Factory orders from Germany and house prices from the UK are the top economic news due on Tuesday.

At 1.45 am ET, unemployment data is due from Switzerland. The jobless rate is seen unchanged at 1.9 percent in February.

At 2.00 am ET, Destatis is scheduled to issue Germany’s factory orders data for January. Economists forecast orders to fall 0.9 percent on month, in contrast to the 3.2 percent increase in December.

Also, UK Halifax house price data is due. House prices are forecast to ease 0.3 percent month-on-month in February, after staying flat in January. In the meantime, industrial production from Norway is due.

At 3.00 am ET, industrial production from Spain and wholesale prices from Austria are due.

At 5.00 am ET, the Hellenic Statistical Authority is scheduled to release Greece GDP data for the fourth quarter.

Red Beans and Rice Feed New Orleans’ Soul

The dish is central to the city’s identity — and central to it is the right bean.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Kayla Stewart

Woman killed, sheriff’s deputy injured during mobile home park fire in Strasburg

One woman was killed and a sheriff’s deputy sustained minor injuries after a fire broke out at a mobile home park near Strasburg.

The blaze sparked at 9:20 a.m. in the 1200 block of County Road 157, the Arapahoe County Sheriff’s Office said on Twitter. The address is associated with the Country Gardens Mobile Home Park.

The woman, who authorities said was in her 60s, died moments after being rescued. She has not been identified.

Sign up to get crime news sent straight to your inbox each day.

ACADIA Pharmaceuticals Stock Slips 7%

Shares of ACADIA Pharmaceuticals Inc. (ACAD) are slipping nearly 7% on Monday morning.

ACAD is currently trading at $18.92, down $1.45 or 7.09%, on the Nasdaq. The stock opened its trading at $20.07 after closing Friday’s trading at $20.37. The stock has traded between $12.24 and $28.06 in the past 52-week period.

On Saturday, Acadia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Daybue for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Daybue is the first and only drug approved for the treatment of Rett syndrome.

With the FDA approval of Daybue, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application.

Acadia Pharmaceuticals said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson.

Rett syndrome is a rare disease that has been diagnosed in 4,500 adults and children in the U.S. The company said it expects to have the drug available in the U.S. by the end of April.